Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
We conducted a study for development of antibody therapy against leukemic stem cells (LSC) that cause a recurrence of leukemia. At first, we identified CD34-negative LSCs that are more undifferentiated than LSCs hitherto known. Then, antibodies against CD34-negative LSCs were produced. Analyzing of target epitopes of this produced antibodies, an antigen were identified as a promising target for a new leukemic treatment. This antibody exerted anti-leukemic cell effects in in vitro experiments.
|